NR4A2 and glioblastoma: Genetic targeting of either heterozygous Nr4a2 (Nr4a2+/−) or microglia-specific Nr4a2 (Nr4a2fl/flCx3cr1cre) changed microglia plasticity in vivo by lowering alternatively activated microglia and increasing CD8+ T cells’ ability to present antigens in GBM.